...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

apceth Names Dr Stefanos Theoharis Chief Business Officer

| Print |
Thursday, 05 September 2013 13:15 (UTC + 2)

apceth logo

Dr Stefanos Theoharis will lead apceth’s business development and business operations and promote the continued expansion of apceth’s GMP manufacturing business.

Munich, Germany, September 5, 2013 / B3C newswire / – Cell-therapy company, apceth GmbH, has announced the expansion of its senior management team with the appointment of Dr Stefanos Theoharis as Chief Business Officer.

In this newly created role, Dr Theoharis will lead apceth’s business development and business operations to maximize the value of the company’s world class clinical and preclinical pipeline. He will also promote the continued expansion of apceth’s GMP manufacturing business.

Dr Theoharis brings broad experience in the life science sector from roles in leading pharma companies, biotech, investment banking and academia. He joins apceth from Antisense Pharma, where he was Head of Business Development. Before that, he held the position of Business Development Director with Roche, where he focused on deals and alliances in Emerging Technologies. He was previously an M&A Analyst in the Life Science team for Lazard.

Dr Theoharis holds a PhD in Cell and Gene Therapy from Imperial College London, where he subsequently worked as a Research Fellow, as well as acting as a transfer consultant for the London Technology Network.

“Apceth is about to start the world’s first clinical trial with genetically modified mesenchymal stem cells in cancer indications, while our trial in Critical Limb Ischemia is advancing, so it’s a very exciting time for us to welcome Stefanos to the team”, said Christine Guenther, CEO of apceth. “His experience will complement our management team and help drive apceth forward.”

Stefanos Theorasis Apceth CIO
Caption: Dr Stefanos Theoharis
Chief Business Officer
apceth GmbH & Co. KG


About apceth

apceth is one of the leading European pioneers in the development, GMP manufacturing and clinical implementation of innovative stem cell-based therapies for the treatment of malignant and non-malignant diseases. apceth combines the principles of stem cell biology with groundbreaking technologies, applying the highest standards for GMP manufacturing, safety regulations and quality control according to the European Regulation for “Advanced Therapy Medicinal Products” (ATMPs). apceth provides novel cell therapy solutions for the treatment of clinical conditions for which no satisfactory treatment options are available to date. The proven know-how in all aspect of ATMP pharmaceutical development and GMP production (GMP manufacturing license, §13 and §20b AMG) enable apceth also to offer the contract manufacturing services for diverse ATMPs.

apceth was founded in 2007 as a start-up company and is privately owned by its founders and private investors.


Contacts

apceth GmbH & Co. KG
Dr. Christine Günther, CEO
Prof. Dr. Ralf Huss, CSO
Max-Lebsche-Platz 30
D-81377 Munich
Germany
Phone: +49 (0)89-7009 608-0
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Media contact

COMMPartners
Rosmarie Dammler, Anne Schardey
Tölzer Straße 12
D-83607 Holzkirchen
Germany
Phone: +49 (0)8024 47013-0
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it